# MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 Diabetes

Study · id `cardio:ct-nct01847144` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01847144](<https://clinicaltrials.gov/study/NCT01847144>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01847144

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 143 participants.

## Technical summary

Registry record NCT01847144. Randomized; no masking; primary purpose basic science. Start 2013-04 (registry gives no type); primary completion 2015-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose basic science
- Phase: Phase 4
- Enrolled: 143 participants (enrolled count; ClinicalTrials.gov record NCT01847144, source copy `cardio:ctgov-nct01847144-2018-06-21`, retrieved 2026-10-26)
- Start date: 2013-04 (registry gives no type) (ClinicalTrials.gov record NCT01847144, source copy `cardio:ctgov-nct01847144-2018-06-21`, retrieved 2026-10-26)
- Primary completion: 2015-02 (actual) (ClinicalTrials.gov record NCT01847144, source copy `cardio:ctgov-nct01847144-2018-06-21`, retrieved 2026-10-26)
- Completion: 2015-02 (actual) (ClinicalTrials.gov record NCT01847144, source copy `cardio:ctgov-nct01847144-2018-06-21`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT01847144, source copy `cardio:ctgov-nct01847144-2018-06-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01847144-2018-06-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 Diabetes
- Acronym: Mastermind
- Condition: Type 2 Diabetes
- Intervention (Drug): Gliclazide 80mg OD
- Intervention (Drug): Sitagliptin 100mg OD
- Lead sponsor: Royal Devon and Exeter NHS Foundation Trust
- Lead sponsor class: OTHER
- Collaborator: University of Exeter
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as a collaborator: University of Exeter (`cardio:org-university-of-exeter`)

## Provenance

Content hash: c29e814c20d91c889bc0b6a4c4016ed7f2fc636851a2cc288e7c9ed96261a0cc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
